China Universal Asset Management Company’s AC Immune ACIU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$38.5K Sell
16,197
-1,655
-9% -$4.56K ﹤0.01% 473
2026
Q1
$49.1K Buy
17,852
+1,490
+9% +$4.63K ﹤0.01% 458
2025
Q4
$51.4K Sell
16,362
-1,238
-7% -$3.9K ﹤0.01% 449
2025
Q3
$50.9K Sell
17,600
-2,567
-13% -$5.8K ﹤0.01% 432
2025
Q2
$40.9K Buy
20,167
+330
+2% +$574 ﹤0.01% 429
2025
Q1
$37.1K Sell
19,837
-1,133
-5% -$2.85K ﹤0.01% 435
2024
Q4
$56.6K Buy
20,970
+1,949
+10% +$6.09K 0.01% 443
2024
Q3
$71.9K Buy
19,021
+7,400
+64% +$25.8K 0.01% 374
2024
Q2
$46.4K Sell
11,621
-7,387
-39% -$24.4K 0.01% 363
2024
Q1
$56.3K Buy
19,008
+9,334
+96% +$33.5K 0.01% 408
2023
Q4
$48.4K Buy
+9,674
New +$31.1K 0.01% 374
2022
Q4
Sell
-783
Closed -$2K 392
2022
Q3
$2K Buy
+783
New +$2.47K ﹤0.01% 344

Other funds holding ACIU

China Universal Asset Management Company's ACIU Position: Q2 2026 in Review

China Universal Asset Management Company reduced its AC Immune (ACIU) stake by 9.3% in Q2 2026, selling an estimated $4.56K and leaving 16,197 shares worth $38.5K. The position accounts for ﹤0.01% of the portfolio, ranked #473.

China Universal Asset Management Company first reported a position in ACIU in Q3 2022 and has held it in 12 quarters since. The position peaked at $71.9K in Q3 2024. 20 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.

  • China Universal Asset Management Company held 16,197 shares of AC Immune worth $38.5K as of Q2 2026.
  • China Universal Asset Management Company sold 1,655 AC Immune shares in Q2 2026, an estimated $4.56K.
  • AC Immune made up ﹤0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #473 holding.
  • China Universal Asset Management Company first reported a position in AC Immune in Q3 2022 and has held it in 12 quarters since.
  • China Universal Asset Management Company's AC Immune position peaked at $71.9K in Q3 2024.
  • 20 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.